Table 2.
Immune responses of viremic EIA-positive and nonviremic EIA-positive injection drug users, as stratified by age and race.
| Response | Viremic EIA-positive subjects, n/N (%)a | Nonviremic EIA-positive subjects n/N (%)a | OR (95% CI) | Exact P |
|---|---|---|---|---|
| T cell proliferation | ||||
| All subjects | 8/21 (38) | 13/17 (76) | 5.28 (1.06–29.2) | .04 |
| Adjustedb for age and race | 4.76 (1.04–27.2) | .07 | ||
| T cell IFN-γ production | ||||
| All subjects | 3/20c (15) | 13/17 (76) | 18.4 (2.84–138) | .0004 |
| Adjustedb for age and race | 37.4 (4.79–981) | .0001 | ||
| Any T cell responsed | ||||
| All subjects | 9/20c (45) | 16/17 (94) | 19.6 (2.04–893) | .003 |
| Adjustedb for age and race | 19.9 (2.46–550) | .002 | ||
| nAbs | ||||
| All subjects | 19/21 (90) | 9/16c (56) | 0.13 (0.01–0.95) | .04 |
| Adjustedb for age and race | 0.07 (0.002–0.60) | .01 |
NOTE. Statistical analyses were performed using StatXact software (version 7; Cytel). CI, confidence interval; IFN, interferon; nAbs, neutralizing antibodies; OR, odds ratio.
a
No. of responders/total no. of subjects (% of subjects who were responders).
b
OR combined over strata was estimated using exact methods with a mid-P–corrected CI. Analysis controlled for sex produced similar results.
c
One subject was not tested.
d
Proliferation or IFN-γ.